Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Increase in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the recipient of a significant growth in short interest in January. As of January 30th, there was short interest totaling 16,753 shares, a growth of 26.7% from the January 15th total of 13,222 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average trading volume of 57,316 shares, the days-to-cover ratio is presently 0.3 days. Based on an average trading volume of 57,316 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.3% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Chemomab Therapeutics in a research report on Monday, December 29th. Zacks Research cut Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $26.50.

Chemomab Therapeutics Price Performance

Shares of NASDAQ CMMB opened at $1.51 on Wednesday. The firm’s fifty day moving average is $1.76 and its 200 day moving average is $2.58. Chemomab Therapeutics has a 52 week low of $1.42 and a 52 week high of $8.24. The company has a market cap of $9.30 million, a price-to-earnings ratio of -0.51 and a beta of 0.56.

Institutional Trading of Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC acquired a new position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 51,710 shares of the company’s stock, valued at approximately $85,000. Kestra Private Wealth Services LLC owned approximately 0.84% of Chemomab Therapeutics at the end of the most recent quarter. Institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.